SG11201404361UA - Methods for increasing the infectivity of viruses - Google Patents
Methods for increasing the infectivity of virusesInfo
- Publication number
- SG11201404361UA SG11201404361UA SG11201404361UA SG11201404361UA SG11201404361UA SG 11201404361U A SG11201404361U A SG 11201404361UA SG 11201404361U A SG11201404361U A SG 11201404361UA SG 11201404361U A SG11201404361U A SG 11201404361UA SG 11201404361U A SG11201404361U A SG 11201404361UA
- Authority
- SG
- Singapore
- Prior art keywords
- infectivity
- viruses
- increasing
- methods
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591047P | 2012-01-26 | 2012-01-26 | |
| PCT/US2013/023047 WO2013112780A1 (en) | 2012-01-26 | 2013-01-25 | Methods for increasing the infectivity of viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404361UA true SG11201404361UA (en) | 2014-09-26 |
Family
ID=48873929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404361UA SG11201404361UA (en) | 2012-01-26 | 2013-01-25 | Methods for increasing the infectivity of viruses |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9890361B2 (en) |
| EP (1) | EP2807252B1 (en) |
| KR (1) | KR20140129054A (en) |
| CN (2) | CN108977412A (en) |
| AU (1) | AU2013212068B2 (en) |
| SG (1) | SG11201404361UA (en) |
| WO (1) | WO2013112780A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| AU2011308496A1 (en) | 2010-10-01 | 2013-05-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP2014511687A (en) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | Engineered nucleic acid delivery and formulation |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (en) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| HRP20220717T1 (en) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modified mrna compositions |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2834358A4 (en) | 2012-04-02 | 2016-03-09 | Moderna Therapeutics Inc | Modified polynucleotides for the production of nuclear proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015051268A2 (en) * | 2013-10-04 | 2015-04-09 | The Johns Hopkins University | Hiv protease inhibitors against picornavirus infection |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| MX2020002348A (en) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Methods of making lipid nanoparticles. |
| JP2022501367A (en) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | Preparation of lipid nanoparticles and method for administration thereof |
| US20230398090A1 (en) * | 2020-03-27 | 2023-12-14 | Beech Tree Labs, Inc. | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523965A (en) | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5141674A (en) | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| GB8522964D0 (en) | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Aerosol |
| EP0249561B1 (en) | 1986-06-12 | 1992-05-13 | The Liposome Company, Inc. | Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| US4839175A (en) | 1986-07-28 | 1989-06-13 | Liposome Technology, Inc. | Liposomes with enhanced retention on mucosal tissue |
| SE8603812D0 (en) | 1986-09-12 | 1986-09-12 | Draco Ab | ADMINISTRATION OF LIPOSOMES TO MAMMALS |
| US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| AU667564B2 (en) * | 1992-09-07 | 1996-03-28 | Virostat (Na) Nv | Method of treating viral infections |
| CA2120197A1 (en) | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
| EP0659885A1 (en) | 1993-12-21 | 1995-06-28 | Akzo Nobel N.V. | Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity |
| US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
| TW497974B (en) | 1996-07-03 | 2002-08-11 | Res Dev Foundation | High dose liposomal aerosol formulations |
| US7169411B1 (en) * | 1997-06-13 | 2007-01-30 | The University of Nebraska Board of Regents | Composition for delivery of biological agents and methods for the preparation thereof |
| GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
| GR1003359B (en) | 1998-12-24 | 2000-04-10 | �.�. ����������� �.�.�.�. | Liposomic niflumic acid-new transdermal anti-inflammatory medicine |
| AU7607900A (en) | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| US20040043380A1 (en) | 2000-11-17 | 2004-03-04 | Hiroshi Miyake | T cell line and use thereof |
| ES2566761T3 (en) | 2002-05-30 | 2016-04-15 | The Scripps Research Institute | Copper Catalyzed Azide and Acetylene Ligation |
| EP1371362A1 (en) | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
| US20050112199A1 (en) | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
| PL2286794T3 (en) | 2003-10-15 | 2016-10-31 | Use of cationic liposomes comprising paclitaxel | |
| US20050214751A1 (en) | 2004-03-02 | 2005-09-29 | Proteologics, Inc. | Inhibition of viral maturation, methods and compositions related thereto |
| US20070020620A1 (en) | 2005-07-14 | 2007-01-25 | Finn M G | Compositions and methods for coupling a plurality of compounds to a scaffold |
| US8299031B2 (en) | 2006-01-25 | 2012-10-30 | Viro Pharmaceuticals Gmbh & Co. Kg | Human semen enhancer of viral infection peptides (SEVI) and their use |
| EP2362912A1 (en) * | 2008-11-14 | 2011-09-07 | Life Technologies Corporation | Compositions and methods for engineering cells |
| US20100203647A1 (en) * | 2008-11-21 | 2010-08-12 | The Rockefeller University | Chemical Reporters of Protein Acylation |
| US20130157924A1 (en) | 2010-04-23 | 2013-06-20 | The Regents Of The University Of California | Reducing transmission of sexually transmitted infections |
| US20120028335A1 (en) * | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| EP2807251B1 (en) * | 2012-01-26 | 2018-01-10 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
-
2013
- 2013-01-25 SG SG11201404361UA patent/SG11201404361UA/en unknown
- 2013-01-25 KR KR20147023700A patent/KR20140129054A/en not_active Application Discontinuation
- 2013-01-25 AU AU2013212068A patent/AU2013212068B2/en not_active Ceased
- 2013-01-25 WO PCT/US2013/023047 patent/WO2013112780A1/en active Application Filing
- 2013-01-25 US US14/374,404 patent/US9890361B2/en active Active
- 2013-01-25 EP EP13740994.2A patent/EP2807252B1/en active Active
- 2013-01-25 CN CN201810948605.1A patent/CN108977412A/en active Pending
- 2013-01-25 CN CN201380006669.5A patent/CN104245925A/en active Pending
-
2018
- 2018-01-09 US US15/865,713 patent/US10808228B2/en active Active
-
2020
- 2020-09-15 US US17/021,163 patent/US11732244B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013112780A1 (en) | 2013-08-01 |
| US20200407698A1 (en) | 2020-12-31 |
| EP2807252B1 (en) | 2017-05-10 |
| AU2013212068B2 (en) | 2018-02-15 |
| CN108977412A (en) | 2018-12-11 |
| EP2807252A1 (en) | 2014-12-03 |
| US20150037288A1 (en) | 2015-02-05 |
| US11732244B2 (en) | 2023-08-22 |
| US20180171306A1 (en) | 2018-06-21 |
| EP2807252A4 (en) | 2015-10-14 |
| US10808228B2 (en) | 2020-10-20 |
| KR20140129054A (en) | 2014-11-06 |
| CN104245925A (en) | 2014-12-24 |
| US9890361B2 (en) | 2018-02-13 |
| AU2013212068A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201404014PA (en) | Methods for increasing the infectivity of viruses | |
| SG11201404361UA (en) | Methods for increasing the infectivity of viruses | |
| IL237275A0 (en) | Compounds for the treatment of paramoxyvirus viral infectiones | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| GB201218933D0 (en) | An entity | |
| EP2806891A4 (en) | Parainfluenza virus 5 based vaccines | |
| GB201321144D0 (en) | Improved oncolytic viruses | |
| IL231132A0 (en) | Viral clearnce methods | |
| HK1212332A1 (en) | Hepatitis c virus inhibitors | |
| IL236450A0 (en) | Process for the preparation of 5-fluoro-1h-pyrazoles | |
| PL399419A1 (en) | Process for the preparation of 4-methoxydihydrochalcone | |
| PL399418A1 (en) | Process for the preparation of 4-methoxydihydrochalcone | |
| EP2887883A4 (en) | Improved scalpel | |
| KR101334557B9 (en) | Cookware | |
| ZA201405824B (en) | Process for the preparation of substituted phenylpropanones | |
| GB201215184D0 (en) | Therapeutic virus | |
| ZA201405954B (en) | Method for assessing the viability of viruses with lymphotropism | |
| EP2826486A4 (en) | Agent for the treatment of hepatitis c virus | |
| GB201211930D0 (en) | Concept for all killer viruses | |
| HU229987B1 (en) | Process for the preparation of pyrimidinyl-piperazines | |
| GB201314063D0 (en) | Virus | |
| GB201213587D0 (en) | Novel endolysin | |
| GB201306812D0 (en) | Virus |